image credit- shutterstock
Ahmedabad-based contract research organization (CRO) Veeda Lifesciences has announced an investment in Mango Sciences, a Boston-based healthcare AI and data company.
With this investment, Veeda intends to leverage AI capabilities to improve the speed, efficiency and quality of clinical trial services across its expanded global network, enabling more diverse and efficient recruitment as well as globally representative patient selection.
Building on the Querent platform™ powered by Mango Sciences' AI, Veeda will effectively use the technology to automate accurate patient identification and expand its reach across Europe.
"Our partnership will make Veeda an AI-driven oncology drug development organisation that can meet the growing demand for diversity in clinical trials, in line with the expectations of regulators and pharmaceutical companies. We will be one of the few oncology CROs with access to this proprietary technology," said Mahesh Bhalgat, Group Executive Director and Managing Director of Veeda Clinical Research Limited.
By deploying the Querent platform™ powered by AI, Veeda will streamline processes, improve data management capabilities, and ensure higher quality standards through broader representation of non-Caucasian populations. This will increase the efficiency of clinical trials through advanced data analytics, benefiting patient matching, trial design and monitoring, while reducing costs and time.
